Clinical case of treatment of chlamydial-candidiasis mixed infection of the vagina and cervix
Abstract
this clinical case demonstrates the successful treatment of a patient with chlamydial-candidiasis mixed infection of the vagina and cervix. During the clinical and laboratory examination of the urogenital contents, a violation of the vaginal microbiocenosis was detected, yeast-like fungi of the genus Candida and Chlamydia trachomatis DNA were verified. Immunological examination showed an increased content of antichlamydial and anticandidiasis immunoglobulins M and G and a decrease in the content of lysozyme in cervical mucus. The patient was prescribed outpatient drug treatment. The complex of drugs included a macrolide antibiotic from the azalide group, an antifungal agent from the triazole group, an inducer of the synthesis of endogenous α- and γ-interferons, a local combined antiseptic preparation containing chlorhexidine bigluconate and dexpanthenol, and a probiotic containing lacto- and bifidobacteria. After the course of treatment, the patient's condition improved, the elimination of Candida fungi and Chlamydia trachomatis was observed, the vaginal microbiocenosis was normalized; the titers of both antichlamydial and anticandida immunoglobulins decreased by 2 times and the level of lysozyme in cervical mucus increased. During the year of observation, no relapses were detected.
The uniqueness of the mixed infection of Candida albicans and Chlamydia trachomatis lies in the fact that the clinical symptoms are erased, since the properties of individual pathogenic organisms do not add up, and a fundamentally new pathogenetic mechanism of disease development arises. This significantly complicates diagnosis and treatment. That is why we have selected a combination of drugs that contribute to the destruction of both pathogens, normalize the vaginal microflora and restore local immunity of the vaginal mucosa and cervix, which provides a stable therapeutic effect and prevents possible relapses. Particular attention was paid to an individual approach to treatment, which included an assessment of concomitant diseases, the level of immune defense and the characteristics of the vaginal microbiocenosis in a particular patient. Thus, this case demonstrates the high effectiveness of complex therapy for chlamydial-candidiasis mixed infection, which is based on modern principles of etiotropic and pathogenetic treatment, takes into account the characteristics of the microbial composition and the state of local immunity. This approach allows achieving stable remission and improving the patient's quality of life. The success of our treatment lies in the fact that with the complete elimination of pathogens, especially in the chronic recurrent course of Chlamydia trachomatis, it became possible to prevent negative complications of this disease, namely the tubo-peritoneal factor of infertility, which allows the patient to realize her reproductive plans in the future.
References
Наказ Міністерства охорони здоров’я України від 15.12.2022 №2264 «Про затвердження стандартів медичної допомоги «Аномальні вагінальні виділення». Клінічна настанова, заснована на доказах – 158 с.
Web Annex B. Evidence-to-decision framework and systematic review to update the WHO treatment recommendations for Chlamydia trachomatis. In: Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis and Treponema pallidum (syphilis), and new recommendations on syphilis testing and partner services. Geneva: World Health Organization; 2024. https://doi.org/10.2471/B09109 . Licence: CC BY-NC-SA 3.0 IGO.
Web Annex C. Evidence-to-decision framework and systematic review for the WHO treatment recommendations for Candida albicans. In: Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts). Geneva: World Health Organization; 2024. https://doi.org/10.2471/B09106 Licence: CC BY-NC-SA 3.0 IGO
Simone Filardo, Marisa Di Pietro, Giulia Tranquilli, Rosa Sessa /Biofilm in Genital Ecosystem: A Potential Risk Factor for Chlamydia trachomatis Infection//Canadian Journal of Infectious Diseases and Medical Microbiology. – 2019. – Issue 1. – 6 p.
Michael D. Kruppa, Jeremy Jacobs, Kelsey King-Hook, Keleigh Galloway, Amy Berry, Jennifer Kintner, Judy D. Whittimore, Rolf Fritz, Robert V. Schoborg and Jennifer V. Hall. Binding of Elementary Bodies by the Opportunistic Fungal Pathogen Candida albicans or Soluble β-Glucan, Laminarin, Inhibits Chlamydia trachomatis Infectivity//Frontiers in Microbiology. – 2019. - Sec. Infectious Agents and Disease. - volume 9/ - 10 p. https://doi.org/10.3389/fmicb.2018.03270
Akwah Lilian, Maboulou Valerie, Mohamadou Mansour, Toukap Milaine, Ngoutane Aicha, Djoulde Ibrahima, Enama Franck, Velhima Adamou, Ngonde Essome Marie Chantal. Intravaginal Practices and Chlamydia Trachomatis and Candida Albicans Infection: A Cross-Sectional Study among Women from Various Regions Residing in the City of Yaoundé- Cameroon/ INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH. - Volume 03. - Issue 2024. DOI : 10.58806/ijhmr.2024.v3i04n02 Page No. 163-169.
Albert Njeru, Joseph Mwafaida. Prevalence of Chlamydia trachomatis and Candida albicans; hospital based study. – 2019. - doi: https://doi.org/10.1101/701201 . 13 p.
Shu-Fang Chiu, Po-Jung Huang, Wei-Hung Cheng, Ching-Yun Huang, Lichieh Julie Chu, Chi-Ching Lee, Hsin-Chung Lin, Lih-Chyang Chen, Wei-Ning Lin, Chang-Huei Tsao, Petrus Tang, Yuan-Ming Yeh and Kuo-Yang Huang/Vaginal Microbiota of the Sexually Transmitted Infections Caused by Chlamydia trachomatis and Trichomonas vaginalis in Women with Vaginitis in Taiwan. – Microorganisms 2021, 9(9), 1864;
https://doi.org/10.3390/microorganisms9091864.
Jianhui Zhao, Jingwei Shui , Lipei Luo , Cailing Ao, Hongqing Lin, Yuanhao Liang, Li Wang, Haiying Wang, Hongliang Chen and Shixing Tang/Identification and characterization of mixed infections of Chlamydia trachomatis via high-throughput sequencing. Frontier Microbiology. 2022 Nov 10;13:1041789. hhtps://doi:10.3389/fmicb.2022.1041789
Madhavi Kirti; Sumathi Muralidhar; Rekha Bharti; Niti Khunger/Mixed infections in sexually transmitted genital discharge diseases: The clinician’s dilemma and the microbiologist’s rescue act/Journal of Clinical Images and Medical Case Reports. – 2023. – Volume 4. – 3 p.
Rebecca Jeanmonod; Venu Chippa; Donald Jeanmonod/Vaginal candidiasis. StatPearls Publishing. – 2024.
Kimberly A. Workowski, MD; Laura H. Bachmann, MD; Philip A. Chan, MD; Christine M. Johnston, MD; Christina A. Muzny, MD; Ina Park, MD; Hilary Reno, MD; Jonathan M. Zenilman, MD; Gail A. Bolan, MD. Sexually Transmitted Infections Treatment Guidelines, 2021. - Recommendations and Reports/ July 23, 2021 / 70(4);1–187.
European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge (2018).
Катерина Пашинська. Candida albicans і вульвовагінальний кандидоз: молекулярні механізми патогенезу та сучасні терапевтичні підходи. Медичні аспекти здоров’я жінки. 2 (154)’2024.
Yen-Pin Lin, Wei-Chun Chen,Chao-Min Cheng, Ching-Ju Shen. Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis. Diagnostics (basal). 2021 Oct 27;11(11):1996. doi:10.3390/diagnostics11111996.

This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN
ISSN 














